𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

✍ Scribed by Stephen M Ansell; Hui Tang; Paul J Kurtin; Patricia A Koenig; David J Inwards; Keith Shah; Steven C Ziesmer; Andrew L Feldman; Radha Rao; Mamta Gupta; Charles Erlichman; Thomas E Witzig

Book ID
117785619
Publisher
The Lancet
Year
2011
Tongue
English
Weight
162 KB
Volume
12
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 trial of rituximab plus hyper-CV
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV